Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Crystal M. Tang"'
Autor:
Siegfried H. Reich, Stephen K. Burley, Spencer Emtage, Stephen R. Wasserman, Kevin Holme, Shane Atwell, Laura A. Pelletier, Lydia Smyth, Devon A. Thompson, Paul A. Sprengeler, Jeff M. Blaney, Tuan H. Do, Barbara C. Leon, Jason Adams, Isabelle A. Rooney, Marijane Russell, Kenneth D. Schwinn, J. Michael Sauder, Steve F. Gessert, Brandon E. Aubol, Marshall C. Peterman, Karen J. Froning, Jeremy D. Felce, Nanni H. Huser, Crystal M. Tang, Katti A. Jessen, Pierre-Yves Bounaud, Christopher R. Smith, Patrick S. Lee, Jorg Hendle, Sean G. Buchanan
Supplementary Tables 1-3, Figures 1-4 from SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b253da2b8af69b57f61a86d3221a13f9
https://doi.org/10.1158/1535-7163.22485138
https://doi.org/10.1158/1535-7163.22485138
Autor:
Siegfried H. Reich, Stephen K. Burley, Spencer Emtage, Stephen R. Wasserman, Kevin Holme, Shane Atwell, Laura A. Pelletier, Lydia Smyth, Devon A. Thompson, Paul A. Sprengeler, Jeff M. Blaney, Tuan H. Do, Barbara C. Leon, Jason Adams, Isabelle A. Rooney, Marijane Russell, Kenneth D. Schwinn, J. Michael Sauder, Steve F. Gessert, Brandon E. Aubol, Marshall C. Peterman, Karen J. Froning, Jeremy D. Felce, Nanni H. Huser, Crystal M. Tang, Katti A. Jessen, Pierre-Yves Bounaud, Christopher R. Smith, Patrick S. Lee, Jorg Hendle, Sean G. Buchanan
Supplementary Figure 1 from SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee53a296e3d5b8a6d460e10e97860b5a
https://doi.org/10.1158/1535-7163.22485141.v1
https://doi.org/10.1158/1535-7163.22485141.v1
Autor:
Siegfried H. Reich, Stephen K. Burley, Spencer Emtage, Stephen R. Wasserman, Kevin Holme, Shane Atwell, Laura A. Pelletier, Lydia Smyth, Devon A. Thompson, Paul A. Sprengeler, Jeff M. Blaney, Tuan H. Do, Barbara C. Leon, Jason Adams, Isabelle A. Rooney, Marijane Russell, Kenneth D. Schwinn, J. Michael Sauder, Steve F. Gessert, Brandon E. Aubol, Marshall C. Peterman, Karen J. Froning, Jeremy D. Felce, Nanni H. Huser, Crystal M. Tang, Katti A. Jessen, Pierre-Yves Bounaud, Christopher R. Smith, Patrick S. Lee, Jorg Hendle, Sean G. Buchanan
The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics. Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers. In other cancers, such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::265be7461b5631c4751aa9dac9de05d6
https://doi.org/10.1158/1535-7163.c.6531795.v1
https://doi.org/10.1158/1535-7163.c.6531795.v1